Azərbaycanca AzərbaycancaБеларускі БеларускіDansk DanskDeutsch DeutschEspañola EspañolaFrançais FrançaisIndonesia IndonesiaItaliana Italiana日本語 日本語Қазақ ҚазақLietuvos LietuvosNederlands NederlandsPortuguês PortuguêsРусский Русскийසිංහල සිංහලแบบไทย แบบไทยTürkçe TürkçeУкраїнська Українська中國人 中國人United State United StateAfrikaans Afrikaans
สนับสนุน
www.wiki3.th-th.nina.az
  • วิกิพีเดีย

ดรอสไพร โนน หร อ โดรสไพร โนน อ งกฤษ Drospirenone เป นยากล มท ใช เป นยาเม ดค มกำเน ดเพ อป องก นการต งครรภ และใช โดยท วไปร

Drospirenone

Drospirenone
www.wiki3.th-th.nina.azhttps://www.wiki3.th-th.nina.az

ดรอสไพรีโนน หรือ โดรสไพรีโนน (อังกฤษ: Drospirenone) เป็นยากลุ่มที่ใช้เป็นยาเม็ดคุมกำเนิดเพื่อป้องกันการตั้งครรภ์ และใช้ โดยทั่วไปรู้จักในชื่อการค้า สลินดา (อังกฤษ: Slynda) และ ยาสมิน (อังกฤษ: Yasmin) ซึ่งผสม ดรอสไพรีโนนเป็น

ดรอสไพรีโนน
image
image
ข้อมูลทางคลินิก
การอ่านออกเสียงDroe-SPY-re-nown
ชื่อทางการค้าAlone: Slynd
ผสม: Angeliq
ผสม: Yasmin, Yasminelle, Yaz, ฯลฯ
ผสม: Nextstellis
ชื่ออื่นDihydrospirenone; Dihydrospirorenone; 1,2-Dihydrospirorenone; MSp; SH-470; ZK-30595; LF-111; 17β-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone
/Professional Drug Facts
ข้อมูลทะเบียนยา
  • US : Drospirenone
ช่องทางการรับยา
; ; ;
รหัส ATC
  • G03AC10 (WHO)
    G03AA12 G03FA17 (ผสม)
กฏหมาย
สถานะตามกฏหมาย
  • AU: (ต้องใช้ใบสั่งยา)
  • US: สั่งจ่ายเท่านั้น
ข้อมูลเภสัชจลนศาสตร์
ชีวประสิทธิผล66–85%
95–97% (to )
การเปลี่ยนแปลงยาตับ (ส่วนใหญ่ -independent (reduction, และ of ), บางส่วนจาก CYP3A4)
• Drospirenone acid
• 4,5-Dihydrodrospirenone 3-sulfate
ครึ่งชีวิตทางชีวภาพ25–33 hours
การขับออกปัสสาวะ, อุจจาระ
ตัวบ่งชี้
ชื่อตามระบบ IUPAC
  • (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimetylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenantrene-17,2'(5'H)-furan]-3,5'(2H)-dione
เลขทะเบียน CAS
  • 67392-87-4 imageY
(PubChem) CID
  • 68873
DrugBank
  • DB01395 imageY
ChemSpider
  • 62105 imageY
  • N295J34A25
  • D03917 imageY
  • CHEBI:50838 imageY
  • CHEMBL1509 imageY
100.060.599
ข้อมูลทางกายภาพและเคมี
สูตรC24H30O3
366.501 g·mol−1
แบบจำลอง 3D ()
  • Interactive image
  • O=C7O[C@@]6([C@@]3([C@H]([C@@H]2[C@@H]4[C@H](/C1=C/C(=O)CC[C@]1(C)[C@H]2CC3)C4)[C@@H]5C[C@@H]56)C)CC7
  • InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 imageY
  • Key:METQSPRSQINEEU-HXCATZOESA-N imageY
  (verify)
image

ผลข้างเคียงที่พบได้บ่อยคือสิว, ปวดหัว, , และ ผลข้างเคียงที่พบได้ยาก เช่น โพทัสเซียมในเลือดสูง และ ดรอสไพรีโนนเป็นยากลุ่มโปรเจสติน (progestin) หรือสังเคราะห์ ฉะนั้นจึงกระตุ้น นอกจากนี้ ดรอสไพรีโนนยังมีฤทธิ์ และ และไม่มีฤทธิ์ทางฮอร์โมนอื่นอีก เนื่องด้วยฤทธิ์ต้านมิเนอโรคอร์ติคอยด์และลักษณะที่ไม่ปรากฏ ยาดรอสไพรีโนนจึงถือกันว่าเป็นยาที่กับ มากกว่าโปรเจสตินตัวอื่น ๆ

ดรอสไพรีโนนจดลิขสิทธิ์ยาในปี 1976 และถูกนำมาใช้ในทางการแพทย์ตั้งแต่ปี 2000 ปัจจุบันมีจำหน่ายทั่วโลก และบางครั้งมักเรียกว่าเป็นโปรเจสติน "เจเนอเรชั่นที่สี่" ปัจจุบัน ดรอสไพรีโนนเป็น (generic drug) ข้อมูลจากปี 2018 พบว่าดรอสไพรีโนนผสมเป็นยาที่มีการสั่งจ่ายมากที่สุดอันดับที่ 167 ในสหรัฐ ด้วยจำนวนการสั่งจ่ายมากกว่า 3 ล้านครั้งในปีนั้น

อ้างอิง

  1. Kuhl, H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137. PMID 16112947. S2CID 24616324.
  2. "Slynd- drospirenone tablet, film coated". DailyMed. สืบค้นเมื่อ 17 April 2021.
  3. Krattenmacher, Rolf (2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. ISSN 0010-7824. PMID 11024226.
  4. Bachmann, Gloria (2009). "Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin". Patient Preference and Adherence. 3: 259–64. doi:10.2147/PPA.S3901. ISSN 1177-889X. PMC 2778416. PMID 19936169.
  5. Wiesinger, Herbert; Berse, Matthias; Klein, Stefan; Gschwend, Simone; Höchel, Joachim; Zollmann, Frank S.; Schütt, Barbara (2015). "Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol". British Journal of Clinical Pharmacology. 80 (6): 1399–1410. doi:10.1111/bcp.12745. ISSN 0306-5251. PMC 4693482. PMID 26271371.
  6. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocr. Rev. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
  7. อ้างอิงผิดพลาด: ป้ายระบุ <ref> ไม่ถูกต้อง ไม่มีการกำหนดข้อความสำหรับอ้างอิงชื่อ Drugs.com
  8. อ้างอิงผิดพลาด: ป้ายระบุ <ref> ไม่ถูกต้อง ไม่มีการกำหนดข้อความสำหรับอ้างอิงชื่อ pmid26598309
  9. Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". Eur J Contracept Reprod Health Care. 5 Suppl 3: 17–24. PMID 11246598.
  10. Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403.
  11. อ้างอิงผิดพลาด: ป้ายระบุ <ref> ไม่ถูกต้อง ไม่มีการกำหนดข้อความสำหรับอ้างอิงชื่อ Ravina2011
  12. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (ภาษาอังกฤษ). John Wiley & Sons. p. 459. ISBN .
  13. อ้างอิงผิดพลาด: ป้ายระบุ <ref> ไม่ถูกต้อง ไม่มีการกำหนดข้อความสำหรับอ้างอิงชื่อ HatcherM.D.2007
  14. อ้างอิงผิดพลาด: ป้ายระบุ <ref> ไม่ถูกต้อง ไม่มีการกำหนดข้อความสำหรับอ้างอิงชื่อ RossoZeichner2016
  15. "Generic Yasmin Availability".
  16. "The Top 300 of 2021". ClinCalc. สืบค้นเมื่อ 18 February 2021.
  17. "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. สืบค้นเมื่อ 18 February 2021.

อ่านเพิ่ม

  • Archer DF (February 2007). "Drospirenone and estradiol: a new option for the postmenopausal woman". Climacteric. 10 Suppl 1: 3–10. doi:10.1080/13697130601114859. PMID 17364592. S2CID 9221524.
  • Archer DF (February 2007). "Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data". J Reprod Med. 52 (2 Suppl): 159–64. PMID 17477110.
  • Archer DF (2007). "Drospirenone, a progestin with added value for hypertensive postmenopausal women". Menopause. 14 (3 Pt 1): 352–4. doi:10.1097/gme.0b013e31804d440b. PMID 17414576.
  • Batur P, Casey PM (February 2017). "Drospirenone Litigation: Does the Punishment Fit the Crime?". J Womens Health (Larchmt). 26 (2): 99–102. doi:10.1089/jwh.2016.6092. PMID 27854556.
  • Bitzer J, Paoletti AM (2009). "Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials". Clin Drug Investig. 29 (2): 73–8. doi:10.2165/0044011-200929020-00001. PMID 19133702. S2CID 10356578.
  • Carranza-Lira S (2009). "Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review". Clin Interv Aging. 4: 59–62. doi:10.2147/CIA.S4117. PMC 2685225. PMID 19503766.
  • Christiansen C (October 2005). "Effects of drospirenone/estrogen combinations on bone metabolism". Climacteric. 8 Suppl 3: 35–41. doi:10.1080/13697130500330283. PMID 16203654. S2CID 42803561.
  • Dickerson V (November 2002). "Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone". J Reprod Med. 47 (11 Suppl): 985–93. PMID 12497673.
  • Fenton C, Wellington K, Moen MD, Robinson DM (2007). "Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris". Drugs. 67 (12): 1749–65. doi:10.2165/00003495-200767120-00007. PMID 17683173. S2CID 46976925.
  • Foidart JM (October 2005). "Added benefits of drospirenone for compliance". Climacteric. 8 Suppl 3: 28–34. doi:10.1080/13697130500330309. PMID 16203653. S2CID 31883491.
  • Foidart JM, Faustmann T (December 2007). "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecol. Endocrinol. 23 (12): 692–9. doi:10.1080/09513590701582323. PMID 18075844. S2CID 12572825.
  • Genazzani AR, Mannella P, Simoncini T (February 2007). "Drospirenone and its antialdosterone properties". Climacteric. 10 Suppl 1: 11–8. doi:10.1080/13697130601114891. PMID 17364593. S2CID 24872884.
  • Han L, Jensen JT (October 2014). "Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive". Expert Opin Pharmacother. 15 (14): 2071–9. doi:10.1517/14656566.2014.949237. PMID 25186109. S2CID 25338932.
  • Heinemann LA, Dinger J (2004). "Safety of a new oral contraceptive containing drospirenone". Drug Saf. 27 (13): 1001–18. doi:10.2165/00002018-200427130-00003. PMID 15471507. S2CID 1773936.
  • Idota N, Kobayashi M, Miyamori D, Kakiuchi Y, Ikegaya H (March 2015). "Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature". Leg Med (Tokyo). 17 (2): 109–15. doi:10.1016/j.legalmed.2014.10.001. PMID 25454533.
  • Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treat Endocrinol. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
  • Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226.
  • Larivée N, Suissa S, Khosrow-Khavar F, Tagalakis V, Filion KB (September 2017). "Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies". BJOG. 124 (10): 1490–1499. doi:10.1111/1471-0528.14623. PMID 28276140.
  • Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A (2015). "Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review". Eur J Contracept Reprod Health Care. 20 (5): 329–43. doi:10.3109/13625187.2015.1050091. PMID 26007631. S2CID 41601833.
  • Li J, Ren J, Sun W (March 2017). "A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome". Eur. J. Obstet. Gynecol. Reprod. Biol. 210: 13–21. doi:10.1016/j.ejogrb.2016.11.013. PMID 27923166.
  • Lopez LM, Kaptein AA, Helmerhorst FM (February 2012). "Oral contraceptives containing drospirenone for premenstrual syndrome". Cochrane Database Syst Rev (2): CD006586. doi:10.1002/14651858.CD006586.pub4. PMID 22336820.
  • Machado RB, Pompei Lde M, Giribela AG, Giribela CG (January 2011). "Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits". Womens Health (Lond). 7 (1): 19–30. doi:10.2217/whe.10.84. PMID 21175386.
  • Mallareddy M, Hanes V, White WB (2007). "Drospirenone, a new progestogen, for postmenopausal women with hypertension". Drugs Aging. 24 (6): 453–66. doi:10.2165/00002512-200724060-00002. PMID 17571911. S2CID 39236155.
  • Motivala A, Pitt B (2007). "Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?". Drugs. 67 (5): 647–55. doi:10.2165/00003495-200767050-00001. PMID 17385938. S2CID 22985078.
  • Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403.
  • Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". Eur J Contracept Reprod Health Care. 5 Suppl 3: 17–24. PMID 11246598.
  • Oelkers W (March 2004). "Drospirenone, a progestogen with antimineralocorticoid properties: a short review". Mol. Cell. Endocrinol. 217 (1–2): 255–61. doi:10.1016/j.mce.2003.10.030. PMID 15134826. S2CID 19936032.
  • Oelkers W (February 2002). "The renin-aldosterone system and drospirenone". Gynecol. Endocrinol. 16 (1): 83–7. doi:10.1080/gye.16.1.83.87. PMID 11915587. S2CID 32410408.
  • Oelkers WH (October 2005). "Drospirenone in combination with estrogens: for contraception and hormone replacement therapy". Climacteric. 8 Suppl 3: 19–27. doi:10.1080/13697130500330341. PMID 16203652. S2CID 42837148.
  • Palacios S, Foidart JM, Genazzani AR (November 2006). "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism" (PDF). Maturitas. 55 (4): 297–307. doi:10.1016/j.maturitas.2006.07.009. :2268/9932. PMID 16949774.
  • Pérez-López FR (June 2008). "Clinical experiences with drospirenone: from reproductive to postmenopausal years". Maturitas. 60 (2): 78–91. doi:10.1016/j.maturitas.2008.03.009. PMID 18468818.
  • Rapkin AJ, Sorger SN, Winer SA (February 2008). "Drospirenone/ethinyl estradiol". Drugs Today. 44 (2): 133–45. doi:10.1358/dot.2008.44.2.1191057. PMID 18389090. S2CID 32413831.
  • Rapkin AJ, Winer SA (May 2007). "Drospirenone: a novel progestin". Expert Opin Pharmacother. 8 (7): 989–99. doi:10.1517/14656566.8.7.989. PMID 17472544. S2CID 6954183.
  • Rapkin RB, Creinin MD (October 2011). "The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium". Expert Opin Pharmacother. 12 (15): 2403–10. doi:10.1517/14656566.2011.610791. PMID 21877996. S2CID 40231903.
  • Rübig A (October 2003). "Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties". Climacteric. 6 Suppl 3: 49–54. PMID 15018248.
  • Scheinfeld NS (2007). "Yaz (3 mg drospirenone/20 microg ethinyl estradiol)". Skinmed. 6 (6): 289. doi:10.1111/j.1540-9740.2007.07338.x. PMID 17975349.
  • Sehovic N, Smith KP (May 2010). "Risk of venous thromboembolism with drospirenone in combined oral contraceptive products". Ann Pharmacother. 44 (5): 898–903. doi:10.1345/aph.1M649. PMID 20371756. S2CID 8248469.
  • Shulman LP (June 2006). "A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone". J Womens Health (Larchmt). 15 (5): 584–90. doi:10.1089/jwh.2006.15.584. PMID 16796485.
  • Simoncini T, Genazzani AR (February 2010). "A review of the cardiovascular and breast actions of drospirenone in preclinical studies". Climacteric. 13 (1): 22–33. doi:10.3109/13697130903437375. PMID 19938948. S2CID 4306359.
  • Sitruk-Ware R (October 2005). "Pharmacology of different progestogens: the special case of drospirenone". Climacteric. 8 Suppl 3: 4–12. doi:10.1080/13697130500330382. PMID 16203650. S2CID 24205704.
  • Thorneycroft IH (November 2002). "Evolution of progestins. Focus on the novel progestin drospirenone". J Reprod Med. 47 (11 Suppl): 975–80. PMID 12497671.
  • Toni I, Neubert A, Botzenhardt S, Gratzki N, Rascher W (September 2013). "Venous thromboembolism in adolescents associated with drospirenone-containing oral contraceptives - two case reports". Klin Padiatr. 225 (5): 266–7. doi:10.1055/s-0033-1353169. PMID 23975850.
  • White WB (February 2007). "Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension". Climacteric. 10 Suppl 1: 25–31. doi:10.1080/13697130601114933. PMID 17364595. S2CID 9451771.
  • Whitehead M (March 2006). "Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data". J Br Menopause Soc. 12 Suppl 1: 4–7. doi:10.1258/136218006775992185. PMID 16513012. S2CID 38095916.
  • Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L, Eisenberg MJ (June 2013). "Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review". BJOG. 120 (7): 801–10. doi:10.1111/1471-0528.12210. PMID 23530659. S2CID 206904730.
  • Zhao X, Zhang XF, Zhao Y, Lin X, Li NY, Paudel G, Wang QY, Zhang XW, Li XL, Yu J (September 2016). "Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis". Gynecol. Endocrinol. 32 (9): 685–689. doi:10.1080/09513590.2016.1183629. PMID 27176003. S2CID 9116138.
  • "Drospirenone in HRT?". Drug Ther Bull. 47 (4): 41–4. April 2009. doi:10.1136/dtb.2009.03.0011. PMID 19357298. S2CID 1909717.
  • "Drospirenone". Drug Information Portal. U.S. National Library of Medicine.

wikipedia, แบบไทย, วิกิพีเดีย, วิกิ หนังสือ, หนังสือ, ห้องสมุด, บทความ, อ่าน, ดาวน์โหลด, ฟรี, ดาวน์โหลดฟรี, mp3, วิดีโอ, mp4, 3gp, jpg, jpeg, gif, png, รูปภาพ, เพลง, เพลง, หนัง, หนังสือ, เกม, เกม, มือถือ, โทรศัพท์, Android, iOS, Apple, โทรศัพท์โมบิล, Samsung, iPhone, Xiomi, Xiaomi, Redmi, Honor, Oppo, Nokia, Sonya, MI, PC, พีซี, web, เว็บ, คอมพิวเตอร์

drxsiphrionn hrux odrsiphrionn xngkvs Drospirenone epnyaklumthiichepnyaemdkhumkaenidephuxpxngknkartngkhrrph aelaich odythwipruckinchuxkarkha slinda xngkvs Slynda aela yasmin xngkvs Yasmin sungphsm drxsiphrionnepndrxsiphrionnkhxmulthangkhlinikkarxanxxkesiyngDroe SPY re nownchuxthangkarkhaAlone Slynd phsm Angeliq phsm Yasmin Yasminelle Yaz l phsm NextstellischuxxunDihydrospirenone Dihydrospirorenone 1 2 Dihydrospirorenone MSp SH 470 ZK 30595 LF 111 17b Hydroxy 6b 7b 15b 16b dimethylene 3 oxo 17a pregn 4 ene 21 carboxylic acid g lactone Professional Drug FactskhxmulthaebiynyaUS Drospirenonechxngthangkarrbya rhs ATCG03AC10 WHO G03AA12 G03FA17 phsm kthmaysthanatamkthmayAU txngichibsngya US sngcayethannkhxmulephschclnsastrchiwprasiththiphl66 85 95 97 to karepliynaeplngyatb swnihy independent reduction aela of bangswncak CYP3A4 Drospirenone acid 4 5 Dihydrodrospirenone 3 sulfatekhrungchiwitthangchiwphaph25 33 hourskarkhbxxkpssawa xuccaratwbngchichuxtamrabb IUPAC 6R 7R 8R 9S 10R 13S 14S 15S 16S 17S 1 3 4 6 6a 7 8 9 10 11 12 13 14 15 15a 16 Hexadecahydro 10 13 dimetylspiro 17H dicyclopropa 6 7 15 16 cyclopenta a phenantrene 17 2 5 H furan 3 5 2H dioneelkhthaebiyn CAS67392 87 4 YPubChem CID68873DrugBankDB01395 YChemSpider62105 YN295J34A25D03917 YCHEBI 50838 YCHEMBL1509 Y100 060 599khxmulthangkayphaphaelaekhmisutrC 24H 30O 3366 501 g mol 1aebbcalxng 3D Interactive imageO C7O C 6 C 3 C H C H 2 C H 4 C H C1 C C O CC C 1 C C H 2CC3 C4 C H 5C C H 56 C CC7InChI 1S C24H30O3 c1 22 6 3 12 25 9 17 22 13 10 14 13 20 16 22 4 7 23 2 21 20 15 11 18 15 24 23 8 5 19 26 27 24 h9 13 16 18 20 21H 3 8 10 11H2 1 2H3 t13 14 15 16 18 20 21 22 23 24 m1 s1 YKey METQSPRSQINEEU HXCATZOESA N Y verify saranukrmephschkrrm phlkhangekhiyngthiphbidbxykhuxsiw pwdhw aela phlkhangekhiyngthiphbidyak echn ophthsesiymineluxdsung aela drxsiphrionnepnyaklumoprecstin progestin hruxsngekhraah channcungkratun nxkcakni drxsiphrionnyngmivththi aela aelaimmivththithanghxromnxunxik enuxngdwyvththitanmienxorkhxrtikhxydaelalksnathiimprakt yadrxsiphrionncungthuxknwaepnyathikb makkwaoprecstintwxun drxsiphrionncdlikhsiththiyainpi 1976 aelathuknamaichinthangkaraephthytngaetpi 2000 pccubnmicahnaythwolk aelabangkhrngmkeriykwaepnoprecstin ecenxerchnthisi pccubn drxsiphrionnepn generic drug khxmulcakpi 2018 phbwadrxsiphrionnphsmepnyathimikarsngcaymakthisudxndbthi 167 inshrth dwycanwnkarsngcaymakkwa 3 lankhrnginpinnxangxingKuhl H 2005 Pharmacology of estrogens and progestogens influence of different routes of administration Climacteric 8 sup1 3 63 doi 10 1080 13697130500148875 ISSN 1369 7137 PMID 16112947 S2CID 24616324 Slynd drospirenone tablet film coated DailyMed subkhnemux 17 April 2021 Krattenmacher Rolf 2000 Drospirenone pharmacology and pharmacokinetics of a unique progestogen Contraception 62 1 29 38 doi 10 1016 S0010 7824 00 00133 5 ISSN 0010 7824 PMID 11024226 Bachmann Gloria 2009 Drospirenone ethinyl estradiol 3 mg 20 mg 24 4 day regimen hormonal contraceptive choices use of a fourth generation progestin Patient Preference and Adherence 3 259 64 doi 10 2147 PPA S3901 ISSN 1177 889X PMC 2778416 PMID 19936169 Wiesinger Herbert Berse Matthias Klein Stefan Gschwend Simone Hochel Joachim Zollmann Frank S Schutt Barbara 2015 Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol British Journal of Clinical Pharmacology 80 6 1399 1410 doi 10 1111 bcp 12745 ISSN 0306 5251 PMC 4693482 PMID 26271371 Stanczyk FZ Hapgood JP Winer S Mishell DR April 2013 Progestogens used in postmenopausal hormone therapy differences in their pharmacological properties intracellular actions and clinical effects Endocr Rev 34 2 171 208 doi 10 1210 er 2012 1008 PMC 3610676 PMID 23238854 xangxingphidphlad payrabu lt ref gt imthuktxng immikarkahndkhxkhwamsahrbxangxingchux Drugs com xangxingphidphlad payrabu lt ref gt imthuktxng immikarkahndkhxkhwamsahrbxangxingchux pmid26598309 Oelkers W December 2000 Drospirenone a new progestogen with antimineralocorticoid activity resembling natural progesterone Eur J Contracept Reprod Health Care 5 Suppl 3 17 24 PMID 11246598 Oelkers W December 2002 Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone a unique progestogen resembling natural progesterone Eur J Contracept Reprod Health Care 7 Suppl 3 19 26 discussion 42 3 PMID 12659403 xangxingphidphlad payrabu lt ref gt imthuktxng immikarkahndkhxkhwamsahrbxangxingchux Ravina2011 Fischer Jnos Ganellin C Robin 2006 Analogue based Drug Discovery phasaxngkvs John Wiley amp Sons p 459 ISBN 9783527607495 xangxingphidphlad payrabu lt ref gt imthuktxng immikarkahndkhxkhwamsahrbxangxingchux HatcherM D 2007 xangxingphidphlad payrabu lt ref gt imthuktxng immikarkahndkhxkhwamsahrbxangxingchux RossoZeichner2016 Generic Yasmin Availability The Top 300 of 2021 ClinCalc subkhnemux 18 February 2021 Drospirenone Ethinyl Estradiol Drug Usage Statistics ClinCalc subkhnemux 18 February 2021 xanephimArcher DF February 2007 Drospirenone and estradiol a new option for the postmenopausal woman Climacteric 10 Suppl 1 3 10 doi 10 1080 13697130601114859 PMID 17364592 S2CID 9221524 Archer DF February 2007 Drospirenone containing hormone therapy for postmenopausal women Perspective on current data J Reprod Med 52 2 Suppl 159 64 PMID 17477110 Archer DF 2007 Drospirenone a progestin with added value for hypertensive postmenopausal women Menopause 14 3 Pt 1 352 4 doi 10 1097 gme 0b013e31804d440b PMID 17414576 Batur P Casey PM February 2017 Drospirenone Litigation Does the Punishment Fit the Crime J Womens Health Larchmt 26 2 99 102 doi 10 1089 jwh 2016 6092 PMID 27854556 Bitzer J Paoletti AM 2009 Added benefits and user satisfaction with a low dose oral contraceptive containing drospirenone results of three multicentre trials Clin Drug Investig 29 2 73 8 doi 10 2165 0044011 200929020 00001 PMID 19133702 S2CID 10356578 Carranza Lira S 2009 Safety efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms a review Clin Interv Aging 4 59 62 doi 10 2147 CIA S4117 PMC 2685225 PMID 19503766 Christiansen C October 2005 Effects of drospirenone estrogen combinations on bone metabolism Climacteric 8 Suppl 3 35 41 doi 10 1080 13697130500330283 PMID 16203654 S2CID 42803561 Dickerson V November 2002 Quality of life issues Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone J Reprod Med 47 11 Suppl 985 93 PMID 12497673 Fenton C Wellington K Moen MD Robinson DM 2007 Drospirenone ethinylestradiol 3mg 20microg 24 4 day regimen a review of its use in contraception premenstrual dysphoric disorder and moderate acne vulgaris Drugs 67 12 1749 65 doi 10 2165 00003495 200767120 00007 PMID 17683173 S2CID 46976925 Foidart JM October 2005 Added benefits of drospirenone for compliance Climacteric 8 Suppl 3 28 34 doi 10 1080 13697130500330309 PMID 16203653 S2CID 31883491 Foidart JM Faustmann T December 2007 Advances in hormone replacement therapy weight benefits of drospirenone a 17alpha spirolactone derived progestogen Gynecol Endocrinol 23 12 692 9 doi 10 1080 09513590701582323 PMID 18075844 S2CID 12572825 Genazzani AR Mannella P Simoncini T February 2007 Drospirenone and its antialdosterone properties Climacteric 10 Suppl 1 11 8 doi 10 1080 13697130601114891 PMID 17364593 S2CID 24872884 Han L Jensen JT October 2014 Expert opinion on a flexible extended regimen of drospirenone ethinyl estradiol contraceptive Expert Opin Pharmacother 15 14 2071 9 doi 10 1517 14656566 2014 949237 PMID 25186109 S2CID 25338932 Heinemann LA Dinger J 2004 Safety of a new oral contraceptive containing drospirenone Drug Saf 27 13 1001 18 doi 10 2165 00002018 200427130 00003 PMID 15471507 S2CID 1773936 Idota N Kobayashi M Miyamori D Kakiuchi Y Ikegaya H March 2015 Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism A case report and review of the literature Leg Med Tokyo 17 2 109 15 doi 10 1016 j legalmed 2014 10 001 PMID 25454533 Keam SJ Wagstaff AJ 2003 Ethinylestradiol drospirenone a review of its use as an oral contraceptive Treat Endocrinol 2 1 49 70 doi 10 2165 00024677 200302010 00005 PMID 15871554 S2CID 209144694 Krattenmacher R July 2000 Drospirenone pharmacology and pharmacokinetics of a unique progestogen Contraception 62 1 29 38 doi 10 1016 S0010 7824 00 00133 5 PMID 11024226 Larivee N Suissa S Khosrow Khavar F Tagalakis V Filion KB September 2017 Drospirenone containing oral contraceptive pills and the risk of venous thromboembolism a systematic review of observational studies BJOG 124 10 1490 1499 doi 10 1111 1471 0528 14623 PMID 28276140 Lete I Chabbert Buffet N Jamin C Lello S Lobo P Nappi RE Pintiaux A 2015 Haemostatic and metabolic impact of estradiol pills and drospirenone containing ethinylestradiol pills vs levonorgestrel containing ethinylestradiol pills A literature review Eur J Contracept Reprod Health Care 20 5 329 43 doi 10 3109 13625187 2015 1050091 PMID 26007631 S2CID 41601833 Li J Ren J Sun W March 2017 A comparative systematic review of Yasmin drospirenone pill versus standard treatment options for symptoms of polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol 210 13 21 doi 10 1016 j ejogrb 2016 11 013 PMID 27923166 Lopez LM Kaptein AA Helmerhorst FM February 2012 Oral contraceptives containing drospirenone for premenstrual syndrome Cochrane Database Syst Rev 2 CD006586 doi 10 1002 14651858 CD006586 pub4 PMID 22336820 Machado RB Pompei Lde M Giribela AG Giribela CG January 2011 Drospirenone ethinylestradiol a review on efficacy and noncontraceptive benefits Womens Health Lond 7 1 19 30 doi 10 2217 whe 10 84 PMID 21175386 Mallareddy M Hanes V White WB 2007 Drospirenone a new progestogen for postmenopausal women with hypertension Drugs Aging 24 6 453 66 doi 10 2165 00002512 200724060 00002 PMID 17571911 S2CID 39236155 Motivala A Pitt B 2007 Drospirenone for oral contraception and hormone replacement therapy are its cardiovascular risks and benefits the same as other progestogens Drugs 67 5 647 55 doi 10 2165 00003495 200767050 00001 PMID 17385938 S2CID 22985078 Oelkers W December 2002 Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone a unique progestogen resembling natural progesterone Eur J Contracept Reprod Health Care 7 Suppl 3 19 26 discussion 42 3 PMID 12659403 Oelkers W December 2000 Drospirenone a new progestogen with antimineralocorticoid activity resembling natural progesterone Eur J Contracept Reprod Health Care 5 Suppl 3 17 24 PMID 11246598 Oelkers W March 2004 Drospirenone a progestogen with antimineralocorticoid properties a short review Mol Cell Endocrinol 217 1 2 255 61 doi 10 1016 j mce 2003 10 030 PMID 15134826 S2CID 19936032 Oelkers W February 2002 The renin aldosterone system and drospirenone Gynecol Endocrinol 16 1 83 7 doi 10 1080 gye 16 1 83 87 PMID 11915587 S2CID 32410408 Oelkers WH October 2005 Drospirenone in combination with estrogens for contraception and hormone replacement therapy Climacteric 8 Suppl 3 19 27 doi 10 1080 13697130500330341 PMID 16203652 S2CID 42837148 Palacios S Foidart JM Genazzani AR November 2006 Advances in hormone replacement therapy with drospirenone a unique progestogen with aldosterone receptor antagonism PDF Maturitas 55 4 297 307 doi 10 1016 j maturitas 2006 07 009 2268 9932 PMID 16949774 Perez Lopez FR June 2008 Clinical experiences with drospirenone from reproductive to postmenopausal years Maturitas 60 2 78 91 doi 10 1016 j maturitas 2008 03 009 PMID 18468818 Rapkin AJ Sorger SN Winer SA February 2008 Drospirenone ethinyl estradiol Drugs Today 44 2 133 45 doi 10 1358 dot 2008 44 2 1191057 PMID 18389090 S2CID 32413831 Rapkin AJ Winer SA May 2007 Drospirenone a novel progestin Expert Opin Pharmacother 8 7 989 99 doi 10 1517 14656566 8 7 989 PMID 17472544 S2CID 6954183 Rapkin RB Creinin MD October 2011 The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium Expert Opin Pharmacother 12 15 2403 10 doi 10 1517 14656566 2011 610791 PMID 21877996 S2CID 40231903 Rubig A October 2003 Drospirenone a new cardiovascular active progestin with antialdosterone and antiandrogenic properties Climacteric 6 Suppl 3 49 54 PMID 15018248 Scheinfeld NS 2007 Yaz 3 mg drospirenone 20 microg ethinyl estradiol Skinmed 6 6 289 doi 10 1111 j 1540 9740 2007 07338 x PMID 17975349 Sehovic N Smith KP May 2010 Risk of venous thromboembolism with drospirenone in combined oral contraceptive products Ann Pharmacother 44 5 898 903 doi 10 1345 aph 1M649 PMID 20371756 S2CID 8248469 Shulman LP June 2006 A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate levonorgestrel and micronized progesterone J Womens Health Larchmt 15 5 584 90 doi 10 1089 jwh 2006 15 584 PMID 16796485 Simoncini T Genazzani AR February 2010 A review of the cardiovascular and breast actions of drospirenone in preclinical studies Climacteric 13 1 22 33 doi 10 3109 13697130903437375 PMID 19938948 S2CID 4306359 Sitruk Ware R October 2005 Pharmacology of different progestogens the special case of drospirenone Climacteric 8 Suppl 3 4 12 doi 10 1080 13697130500330382 PMID 16203650 S2CID 24205704 Thorneycroft IH November 2002 Evolution of progestins Focus on the novel progestin drospirenone J Reprod Med 47 11 Suppl 975 80 PMID 12497671 Toni I Neubert A Botzenhardt S Gratzki N Rascher W September 2013 Venous thromboembolism in adolescents associated with drospirenone containing oral contraceptives two case reports Klin Padiatr 225 5 266 7 doi 10 1055 s 0033 1353169 PMID 23975850 White WB February 2007 Drospirenone with 17beta estradiol in the postmenopausal woman with hypertension Climacteric 10 Suppl 1 25 31 doi 10 1080 13697130601114933 PMID 17364595 S2CID 9451771 Whitehead M March 2006 Hormone replacement therapy with estradiol and drospirenone an overview of the clinical data J Br Menopause Soc 12 Suppl 1 4 7 doi 10 1258 136218006775992185 PMID 16513012 S2CID 38095916 Wu CQ Grandi SM Filion KB Abenhaim HA Joseph L Eisenberg MJ June 2013 Drospirenone containing oral contraceptive pills and the risk of venous and arterial thrombosis a systematic review BJOG 120 7 801 10 doi 10 1111 1471 0528 12210 PMID 23530659 S2CID 206904730 Zhao X Zhang XF Zhao Y Lin X Li NY Paudel G Wang QY Zhang XW Li XL Yu J September 2016 Effect of combined drospirenone with estradiol for hypertensive postmenopausal women a systemic review and meta analysis Gynecol Endocrinol 32 9 685 689 doi 10 1080 09513590 2016 1183629 PMID 27176003 S2CID 9116138 Drospirenone in HRT Drug Ther Bull 47 4 41 4 April 2009 doi 10 1136 dtb 2009 03 0011 PMID 19357298 S2CID 1909717 Drospirenone Drug Information Portal U S National Library of Medicine

วันที่เผยแพร่: มิถุนายน 30, 2024, 03:51 am
อ่านมากที่สุด
  • มกราคม 01, 2025

    ชุมชนเมืองนิยม

  • ธันวาคม 31, 2024

    ค่ายทันเดอร์โคฟ

  • ธันวาคม 31, 2024

    คำรณวิทย์ ธูปกระจ่าง

  • ธันวาคม 31, 2024

    คริส เรดฟิลด์

  • ธันวาคม 31, 2024

    คริสท็อฟ นีมัน

รายวัน

  • เนื้อหาเสรี

  • แถบดาวเคราะห์น้อย

  • จักรพรรดิฮันเซ

  • แม่น้ำโจกันจิ

  • อักษรเบรลล์

  • พ.ศ. 2241

  • พระราชวังไวต์ฮอล

  • ดาวอังคาร

  • บุรจญ์เคาะลีฟะฮ์

  • ดูไบ

NiNa.Az - สตูดิโอ

  • วิกิพีเดีย

การลงทะเบียนจดหมายข่าว

โดยการสมัครรับรายชื่อผู้รับจดหมายของเราคุณจะได้รับข่าวสารล่าสุดจากเราเสมอ
ได้รับการติดต่อ
ติดต่อเรา
DMCA Sitemap Feeds
© 2019 nina.az - สงวนลิขสิทธิ์.
ลิขสิทธิ์: Dadaş Mammedov
สูงสุด